{"nctId":"NCT02734810","briefTitle":"SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis","startDateStruct":{"date":"2016-06","type":"ACTUAL"},"conditions":["Exocrine Pancreatic Insufficiency","Cystic Fibrosis"],"count":15,"armGroups":[{"label":"Part A","type":"EXPERIMENTAL","interventionNames":["Drug: Liprotamase Powder for Oral Solution"]},{"label":"Part B","type":"EXPERIMENTAL","interventionNames":["Drug: Liprotamase Powder for Oral Solution"]}],"interventions":[{"name":"Liprotamase Powder for Oral Solution","otherNames":["Liprotamase"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* For Part A: males or females â‰¥7 years of age\n* For Part B: males or females 28 days to \\<7 years\n* Diagnosis of cystic fibrosis based on presentation, genotype and/or sweat chloride\n* Low fecal elastase\n* Fair-to-good nutritional status\n\nExclusion Criteria:\n\n* History or diagnosis of fibrosing colonopathy\n* Distal intestinal obstruction syndrome in 6 months prior to screening\n* Receiving enteral tube feedings\n* Chronic diarrheal illness unrelated to pancreatic insufficiency\n* Liver abnormalities, or liver or lung transplant, or significant bowel resection","healthyVolunteers":false,"sex":"ALL","minimumAge":"28 Days","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Safety","description":"Number of subjects reporting 1 or more adverse events","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":15},"commonTop":["Infective exacerbation of cystic fibrosis","Aspartate aminotransferase increased"]}}}